Thursday, December 15, 2022
- Opioid Treatment Programs: New Information for 2023
- Part B Immunosuppressive Drug Benefit: Check Medicare Eligibility
- Home Health Quality Reporting Program: Get Final OASIS-E Instrument
- DMEPOS Fee Schedule: CY 2023 Update
- HCPCS Codes & Clinical Laboratory Improvement Amendments Edits: April 2023
- Home or Residence Services: Billing Instructions
- National Coverage Determination 200.3: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
The CY 2023 Physician Fee Schedule final rule includes information for Medicare-enrolled opioid treatment programs (OTPs):
- Revises pricing methodology for drug component of methadone weekly bundle and add-on code for take-home methadone supplies
- Modifies payment rate for individual therapy in non-drug component of the bundled payments for episodes of care
- Allows OTP intake add-on code to initiate treatment with buprenorphine provided via 2-way audio-video communications technology or audio-only technology when audio-video technology isn’t available and all requirements are met
- Extends the flexibility through the end of CY 2023 to provide periodic assessments via audio-only when video isn’t available, when authorized by SAMHSA and DEA
- Clarifies OTPs can bill for medically reasonable and necessary services provided via mobile units
We updated the OTP webpages with this and other new information.
Starting January 1, 2023, Medicare will offer a new benefit that helps continue to pay for immunosuppressive drugs. The Part B immunosuppressive drug (Part B-ID) benefit is for patients who will lose ESRD Medicare coverage 36 months after a kidney transplant and who don’t have, and don’t expect to have, certain other types of health care coverage. The new benefit only covers immunosuppressive drugs and no other items or services.
When you check patient eligibility for this benefit, the response may indicate:
- Part B-ID coverage effective as early as January 1, 2023, with enrollment reason code “P-Part B Immunosuppressive Drug Benefit”
- Noncoverage for all items and services except immunosuppressive drugs
- Qualified Medicare Beneficiary (QMB) program periods (only when a patient is enrolled in QMB)
If you need help, contact your eligibility service provider.
You can’t bill QMB patients for Medicare cost-sharing, including deductibles, coinsurance, and copayments.
Get the final Outcome and Assessment Information Set Version E (OASIS-E) instrument effective January 1, 2023.
The following clarifies messaging from December 8.
The Power Mobility Devices booklet explains how to properly document and bill for power mobility devices (PMDs). Follow these steps to bill for PMDs:
- Obtain the Standard Written Order (SWO)
- Make a prior authorization request
- Complete a home assessment
- Keep the following documents: SWO, face-to-face visit supporting documents, written home assessment report, and proof of delivery
- Review all information to avoid improper payments
An Office of Inspector General report stated that Medicare improperly paid claims for PMD repairs. To properly bill for PMD repairs:
- Show repairs are reasonable, necessary, or meet the requirements
- Document labor time adequately
- Show that DMEPOS suppliers must provide repair warrantees
- Specify that wheelchair repair costs can’t exceed a certain amount over a device’s 5-year lifetime
- 42 CFR 414.210
- Section 110.2 Medicare Benefit Policy Manual, Chapter 15
- Section 510.1 Medicare Program Integrity Manual, Chapter 5
CMS added a new ICD-10-CM diagnosis code for coverage of intravenous immune globulin treatment of primary immune deficiency diseases in the home:
- D81.82: Activated Phosphoinositide 3-kinase Delta Syndrome
- Effective October 1, 2022
- Section 50.6 Medicare Benefit Policy Manual, Chapter 15
- Instruction to your Medicare Administrative Contractor
Learn about this annual update:
- Fee schedule amounts for new and existing codes
- Payment policy changes
Learn about new and discontinued HCPCS codes.
- Care settings
National Coverage Determination 200.3: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
Learn about coverage for:
- FDA-approved monoclonal antibodies for the treatment of Alzheimer’s Disease
- CMS-approved studies
During patient mood interviews, help patients select how often they have symptoms by showing them the new PHQ-2 to 9 cue card.
This newsletter is current as of the issue date. View the complete disclaimer.
The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health and Human Services (HHS).